Table 2.
Donor specific antibodies: characteristics, kinetics and management.
| Patients (n = 19) | |
|---|---|
| Baseline DSA characteristics (n, %) | |
| • DSA anti-MHC class I only | 10 (53) |
| • Intensity > 5000 MFI | 6 |
| • DSA anti-MHC class II only | 4 (21) |
| • Intensity > 5000 MFI | 1 |
| • DSA anti-MHC class I and II | 5 (26) |
| • Intensity > 5000 MFI | 5 |
| After desensitization strategy, prior to infusion | |
| • Median reduction of intensity (median %, range)* | 100 (20-100) |
| • Patients with detectable DSA at infusion (n, %) | 3 (16) |
| • Intensity > 5000 MFI | 2 |
| Complement fixation techniques available (n, %) | 6 (31) |
| • Positive C3d fixation | 6 |
| Increase after infusion (n, %) | 1 (5) |
| • Intensity >5000 MFI | 1 |
| Desensitization treatment used (n, %): | |
| • Rituximab | 17 (90) |
| • IGIV | 13 (68) |
| • MMF | 12 (63) |
| • TPE | 11 (58) |
| • Incompatible platelet transfusion | 9 (47) |
| • Buffy coat | 6 (31) |
| • Tacrolimus | 5 (26) |
| • Steroids | 1 (5) |
We identified a total of 20 haplo-HSCT performed with DSAs in 19 patients. Data from the second haplo-HSCT of the patient with 2 procedures is not shown in this Table. DSA, donor-specific antibodies; MHC, major histocompatibility complex; MFI, immunofluorescence intensity; IGIV, intravenous immunoglobulin; MMF, mofetil mycophenolate; TPE, therapeutic plasma exchange.
*mean 74%.